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stem cell leukemia during nephrogenesis.
Background. In vertebrates the hematopoietic and renal tis-
sues share a common mesodermal origin. Recently, we have
analyzed global gene expression during human nephrogene-
sis and observed up-regulation of stem cell leukemia (SCL),
a transcription factor critical for hematopoietic and endothe-
lial lineage specification. Here we characterize the expression
of SCL along with its distinct 3′ hematopoietic and endothelial
enhancer (SCL 3′En) during kidney development.
Methods. mRNA and protein expression of SCL were exam-
ined in developing murine and human kidneys by quantitative
reverse transcription-polymerase chain reaction (RT-PCR) and
immunohistochemistry. The activity of SCL 3′En was examined
by X-galactosidase (X-gal) staining of embryonic kidneys ob-
tained from SCL +6E5/lacZ/3′En transgenic mice and by re-
porter lacZ assay in various renal cell lines.
Results. We found developmental regulation of SCL mRNA
with highest levels of expression in embryonic day 17 (E17)
mouse kidneys and lowest in postnatal and adult kidneys.
Immunostaining of human fetal kidneys demonstrated the
protein predominantly in the nephrogenic cortex and par-
ticularly in mesenchymal cells and developing glomeruli.
Similarly, SCL +6E5/lacZ/3′En transgenic kidneys showed
prominent lacZ staining in cells resembling undifferentiated
mesoderm cells in close proximity to S and comma-shaped
primitive nephrons and in peritubular and glomerular vessel
endothelium. The SCL 3′En was activated in the human em-
bryonic kidney cell line (HEK 293), but not in cell lines derived
from adult kidney.
Conclusion. These observations suggest a possible role for
SCL in renal vasculogenesis. Undifferentiated mesenchymal
cells expressing SCL during early nephrogenesis might repre-
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sent putative progenitors that can simultaneously give rise to
kidney, blood, and endothelium.
The kidney is derived from the ureteric bud and the
metanephrogenic mesenchyme, and these two progeni-
tor tissues differentiate into more than 26 different cell
types in the adult kidney. The ureteric bud contains the
precursor of the epithelial cells of the collecting duct and
the renal mesenchyme contains precursors of all the ep-
ithelia of the rest of the nephron [1]. Recent in vitro
[2] and in vivo [3, 4] data suggest that cells residing in
the metanephric mesenchyme are pluripotent and can
differentiate, in addition to renal epithelia, into nonre-
nal derivatives especially of mesodermal origin, including
cartilage, bone, myofibroblasts, and also blood and blood
vessels.
The stem cell leukemia (SCL) gene (also known as
TAL-1) encodes a basic helix-loop-helix (bHLH) protein
that is commonly activated in T-cell leukemia [5]. SCL
deficient mice die in utero between E9.5-10.5 with no ev-
idence of blood formation [6, 7]. In knockout mice, yolk
sac cultures confirm the absence of hemopoietic progen-
itors, while chimera analysis shows that SCL−/− ES cells
are unable to contribute to any hemopoietic lineage [8,
9]. Furthermore, examination of SCL−/− embryoid bod-
ies [10] demonstrates a complete failure of expression of
hemopoietic genes. Thus, SCL acts as a critical regulator
of hemopoiesis with a crucial function in the formation
of hemopoietic stem cells (HSCs) [11]. The observation
that SCL knockout mice harbor a severe defect in the
development of yolk sac blood vessels along with trans-
genic rescue experiments proved that SCL is required for
blood vessel development [6, 7, 12]. SCL also plays an im-
portant role in the specification of endothelial precursors
[13]. In zebra fish development, SCL is expressed in a
population of putative hemangioblasts, which give rise to
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hemopoietic and endothelial progenitors. Ectopic SCL
expression greatly increased the number of heman-
gioblasts and also resulted in excessive blood and
endothelial development at the expense of other meso-
dermal cell fates [14]. SCL is capable, therefore, of speci-
fying hemangioblast development from early mesoderm.
Transcriptional regulatory elements of the SCL gene
have been recently characterized in detail [15, 16]. A 3′
enhancer (termed SCL 3′En) localized 19 kb downstream
of exon 1 of the SCL gene was shown to have specificity
for the SCL exon 4 promoter and to display particularly
striking properties. It directed SCL expression to HSCs
and endothelium and their bipotential precursors, the he-
mangioblast, and was suggested to function as a pivotal
element responsible for integrating signals necessary for
lineage commitment to HSCs and blood cell formation
[11].
We have recently profiled gene expression during nor-
mal human kidney development and in developing hu-
man embryonic kidney precursors that were transplanted
into immunodeficient mice [17]. Similar gene expression
profiles, comprised of well-known regulators of renal de-
velopment and genes that previously had no recognized
role, were determined for both normal and transplanted
human kidneys. Among the genes that were surprisingly
up-regulated throughout nephrogenesis was SCL. To be-
gin to identify the potential role of SCL in the devel-
opment of the metanephros, the direct precursor of the
adult kidney, we have determined the expression of SCL




Normal human 10-, 14-, and 20-week gestation kid-
neys were obtained following curettage of elective abor-
tions. Studies with human embryonic kidney tissue were
approved by the Helsinki Ethical Committee. Normal
murine embryonic and postnatal kidneys were obtained
from time-dated pregnant balb/c mice (Weizmann Insti-
tute of Science Breeding Laboratory, Rehovot, Israel).
Transgenic embryonic kidneys were obtained from time-
dated pregnant SCL +6E5/lacZ/3′En transgenic mice.
The preparation of the SCL +6E5/lacZ/3′En transgenic
mice line 2296 has been previously described by Sanchez
et al [15].
Cell lines
293-T, U2OS, MDCK, NIH-3T3, transformed NIH-
3T3, and COS-7 cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
5% to 10% bovine calf serum (BCS), 2 mmol/L glu-
tamine, 100 U/mL penicillin, and 100 lg/mL strepto-
mycin.
Vectors
The +6E5/lacZ/3′En vector has been described in de-
tail by Sanchez et al [15]. Briefly, the vector contains a
2.4 kb Sau3AI/Nde1 fragment starting 6 kb downstream
of SCL promoter 1a with the lacZ gene fused to it and a
3′En (a 5.5 kb BglII/BglII fragment starting 14 kb down-
stream of SCL promoter 1a) that is located downstream
of the lacZ gene (all cloned into pGL-2 vector).
The renila luciferase and cytomegalovirus (CMV)-lacZ
reporter vectors encode for renila luciferase and lacZ re-
porter genes, respectively, under the regulation of CMV
minimal promoter.
RNA preparation
Total RNA was isolated from pooled mouse embryonic
kidneys at gestational day 13, 14, 15, and 17, postnatal 1
day and 2 weeks, and 90-day-old adult kidneys (N = 3
to 5 kidneys in each time point). Dissected tissues were
immediately frozen in liquid nitrogen before RNA iso-
lation. Total RNA was purified by using Tri-reagent iso-
lation kits (Molecular Research Center, Cincinnati, OH,
USA), according to the manufacturer’s protocol.
cDNA array hybridization
We used the human 1.2 expression arrays (broad-
coverage arrays) of human cDNAs spotted on a nylon
membrane, which contain 1176 cDNAs (Atlas Filter Ar-
rays) (Clontech Laboratories, Palo Alto, CA, USA), as
previously demonstrated [17]. The filters also include
housekeeping control cDNAs. Following RNA isolation,
total RNAs were treated with Dnase I according to
the manufacturer’s protocol and used for cDNA syn-
thesis. A 3 lL mix containing 5 lg of total RNA and
1 lL of 10 × commercial dialysis solution (CDS) primer
mix (specific for each filter array, provided by manufac-
turer) (Clontech Laboratories) was incubated at 70◦C
for 2 minutes followed by incubation at 48◦C for 2 min-
utes. To this mix, 8 lL of master mix [containing 2 lL
5 × reaction buffer, 1 lL 10 × desoxynucleoside
triphosphate (dNTP) mix, 3.5 lL [−32P] desoxyadeno-
sine triphosphate (dATP) (3000 Ci/mmol, 10 mCi/mL)
(Amersham/Pharmacia Biotech, Buckinghamshire, UK),
0.5 lL 100 mmol/L dithiothreitol (DTT), and 1 lL
Moloney murine leukemia virus (MMLV) reverse tran-
scriptase (50 U/lL)] were added, mixed, and incubated
for 25 minutes at 48◦C. The reaction was terminated by
adding 1 lL of 10 × termination mix at room temperature.
The radioactively labeled cDNA mix was fractionated
on a Chroma Spin-200 column (Clontech Laboratories)
and fractions that comprise the first peak of radioactivity
were pooled for each cDNA synthesis reaction. In each
set of hybridization, equal counts were taken for con-
trol and experimental labeled cDNA probes. The labeled
cDNA probe was then mixed with 1/10 volume of 10 ×
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denaturing solution [1 mol/L NaOH, 10 mmol/L
ethylenediaminetetraacetic acid (EDTA)] and incubated
at 68◦C for 20 minutes followed by the addition of 5
lL (1 lg/lL) of cot-1 DNA and an equal volume of
2 × neutralizing solution (1 mol/L NaH2PO4, pH 7.0),
and incubated at 68◦C for 10 minutes. Denatured, la-
beled cDNA was then added to 5 mL of ExpressHyb
solution (Clontech Laboratories) with 1 mg of sheared
salmon sperm DNA (Sigma, St. Louis, MO, USA) and
mixed. This hybridization solution was added to the
Atlas cDNA Expression Array membrane, which was
prehybridized in 10 mL of ExpressHyb hybridization
solution at 68◦C for 1 hour. Hybridization preceded
overnight at 68◦C in a roller bottle. Membranes were
washed once with prewarmed 2 × standard sodium cit-
rate (SSC)/1% sodium dodecyl sulfate (SDS) for 30 min-
utes and once or twice with 0.5 × SSC/0.5% SDS for
30 minutes at 68◦C with constant agitation. The mem-
branes were exposed to Fuji x-ray films at 70◦C with in-
tensifying screens.
cDNA generation and real-time quantitative polymerase
chain reaction
cDNA was generated using Reverse-It 1st Strand Syn-
thesis Kit (AB Gene, catalog no. AB-0789/B; Epsom,
UK) with random decamers, following manufacturer’s
instructions.
Real-time quantitative polymerase chain reaction
(RQ-PCR) assays were developed to determine the level
of expression of SCL. SCL expression was normalized
with b-actin expression as internal standard. Forward
and reverse primers were designed in exon-intron junc-
tions in order to eliminate DNA contamination. Primers
(Eisenberg Bros., Ltd., Givat Shmuel, Israel) were de-
signed according to primer express software guidelines
(Perkin-Elmer/Applied Biosystems, Foster City, CA,
USA): SCL forward primer, 5′-CATGTTCACCAAC
AACAACCG-3′; SCL reverse primer, 5′-GGTGTGA
GGACCATCAGAAATCTC-3′; b-actin forward primer,
5′-TCCTGGCCTCACTGTCCAC-3′; and b-actin re-
verse primer, 5′-GTCCGCCTAGAAGCACTTGC-3′.
The real-time PCR reactions were performed in a to-
tal volume of 20 lL containing 500 nmol/L of each for-
ward and reverse primers and Master Mix for Syber
Green (Applied Biosystems, Foster City, CA, USA) with
cDNA equivalent to 100 ng of RNA (for each time
point) using Applied Biosystems 7900HT prism real-
time PCR instrument (TaqMan) (Perkin-Elmer/Applied
Biosystems). PCR amplification included a first step of
10 minutes at 95◦C followed by 40 cycles of amplification
(95◦C for 15 seconds and 60◦C for 60 seconds). Standard
curves were generated using RNA extracted from mouse
spleen (which expresses SCL) diluted in four log steps.
Ratio was calculated by dividing each gene expression
with that of an internal standard in each sample. These
ratios were compared between the different time points
(average ± SEM). Three independent experiments were
performed for each time point analyzed.
Immunohistology
Immunohistochemistry for SCL was done using a
monoclonal anti-SCL/TAL-1 antibody (2TL242), kindly
provided by Dr. Karen Pulford, Oxford, United King-
dom. The 2TL242 antibody raised against recombinant
SCL/TAL-1 protein has been previously characterized
for immunohistochemistry and was shown to specifi-
cally recognize TAL-1 polypeptides of molecular weight
39 and 41 kD (full length) [18, 19]. Briefly, sections of
5 lm were mounted on superfrost/plus glass (Menzel,
Glazer, Braunschweig, Germany) and processed by the
labeled (streptavidin) avidin-biotin (LAB-SA) method
using a histostain plus kit (Zymed, San Francisco, CA,
USA). Heat-induced antigen retrieval was performed by
controlled microwave treatment using an H2800 model
processor (Energy Bean Sciences, Inc., Agawan, MA,
USA) in 10 mmol/L citrate buffer, pH 6.0, for 10 min-
utes at 97◦C. The sections were treated with 3% H2O2
for 5 minutes. Consecutive sections were incubated for
1 hour with the 2TL242 antibody. Negative control in-
cubations were performed by substituting nonimmune
serum for the primary antibody. Biotinylated second an-
tibody was applied for 10 minutes followed by incubation
with horseradish peroxidase–conjugated streptavidin
(HRP-SA) for 10 minutes. Following each incubation, the
slides were washed thoroughly with Optimax wash buffer
(Biogenex, San Ramon, CA, USA). The immunoreaction
was visualized by an HRP-based chromogen/substrate
system, including diaminobenzidine (DAB) (brown)
chromogen (liquid DAB substrate kit) (Zymed). The
sections were then counterstained with Mayer’s hema-
toxylin, dehydrated, and mounted for microscopic
examination.
b-Galactosidase detection
X-galactosidase (X-gal) staining was performed as
previously described [15]. Embryonic kidneys were in-
cubated overnight in staining solution. b-galactosidase
(b-gal) expression was visualized in less than 1 hour. Prior
to sectioning, the embryos were dehydrated with increas-
ing concentrations of ethanol and mounted in paraffin
wax. Six to 10 mm sections were counterstained with neu-
tral red.
Transient transfection and reporter assays
The 293-T and U2OS cell lines were transfected using
calcium phosphate method. The NIH-3T3, transformed
NIH-3T3, COS-7, and Madin-Darby canine kidney
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Fig. 1. Stem cell leukemia (SCL) gene ex-
pression in the developing kidney. (A) Hy-
bridization to cDNA of SCL on broad-
coverage human expression arrays when
RNA used for probes was derived from
normal human 12-, 16-, and 20-week-
old gestation kidneys (arrows point to
SCL). (B) Quantitative reverse transcription-
polymerase chain reaction (RT-PCR) analy-
sis of SCL mRNA levels in the developing
mouse kidney. Shown is a representative ex-
ample of three independent experiments. To-
tal RNA was isolated from pooled mouse em-
bryonic (E) kidneys (N = 3 to 5 kidneys in
each time point). (C) A representative am-
plification plot of the real-time RT-PCR re-
action shows the SCL expression differential
between embryonic day 17 and postnatal 2
weeks kidneys as compared to equal b-actin
expression in both time points. Fold expres-
sion denotes the relative expression of SCL
compared with adult kidney.
(MDCK) were transfected using lipofectamine plus
reagent (Invitrogen, Carlsbad, CA, USA) according to
manufacturer’s protocols. Briefly, cells were plated in 24-
well plates the day before transfection. Total DNA and
lipofectamine plus reagent amounts were according to
cell type and manufacturer’s protocol. The transfection
was done in 250 lL volume of antibiotic-free media and
finally 1 mL media was added to the cells 3 hours later. For
the reporter assays, cells were harvested 36 to 48 hours
after transfection and lysed with Promega reporter ly-
sis buffer (Promega, Madison, WI, USA). LacZ readings
were normalized according to the renila luciferase vector
readings and the CMV-lacZ reporter vector served as a
positive control in each cell line.
RESULTS
SCL mRNA expression in developing kidneys
A representative section from the atlas human 1.2 ar-
ray (Clontech Laboratories), demonstrating positive hy-
bridization to SCL cDNA filter when RNA used for
probes was derived from 12-, 16-, and 20-week-old hu-
man gestation kidneys is shown in Figure 1A. If SCL
plays a role in the regulation of kidney development, it
is expected that SCL expression would be developmen-
tally regulated. To test this hypothesis, we quantitatively
analyzed SCL transcripts in developing murine kidneys
of different gestational ages. As shown in Figure 1B and
C, SCL mRNA is significantly higher in the embryonic
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Fig. 2. Immunolocalization of stem cell leukemia (SCL) in developing
human kidneys. (A to F) Different sections of a 10-week-old human
gestation kidney nephrogenic cortex. (A and B) Low magnification
(original, ×40) and (D to F) and higher magnification (original, ×100)
clearly show in all instances positive staining in metanephric mesenchy-
mal cells (mc) and in few cells of the comma (c) and S (s)-shaped prim-
itive nephrons. (C) Control section of the nephrogenic cortex without
the 2TL242 antibody demonstrates minimal background staining with
no staining in mesenchymal cells. (G to J) Sections of more mature
fetal kidneys showing in (G) low magnification (original, ×40), posi-
tive staining for SCL in developing glomeruli (arrowheads), which is
shown in high magnification (original, ×100) in (I and J) to be localized
to developing glomerular capillaries (arrowheads) and intracapillary
erythrocytes (J, arrow). (H) Control section of developing glomeruli
without the 2TL242 antibody demonstrates minimal background stain-
ing.
kidneys and rapidly falls after birth, with the lowest levels
in the adult kidney. SCL mRNA levels are highest in the
embryonic day 17 (E17) kidney, the time of appearance
of well-vascularized glomeruli. Interestingly we also ob-
served a slight but consistent reduction in SCL mRNA
levels during transition from early nephrogenesis to a
more mature stage (E13 to E14) (Fig. 1B). Thus, SCL
is expressed during embryonic nephrogenesis in a devel-
opmentally regulated manner.
Immunolocalization of SCL in the developing kidney
SCL-expressing cells were mapped in serial sections of
the developing human kidney. As shown in low magnifica-
tion (Fig. 2A and B), SCL is localized to the nephrogenic
cortex of a 10-week-old human gestation kidney, particu-
larly in renal mesenchyme, but not in ureteric buds, devel-
oping comma-shaped nephron, or more mature tubules.
Several fields of the nephrogenic cortex shown in higher
magnification in Figure 2D to F clearly demonstrate pos-
itive staining of clusters of mesenchymal cells, some of
which are in close proximity to comma and S-shaped bod-
ies (Fig. 2E and F, respectively). Staining is also seen in
few cells in the early nephron precursors. Immunohysto-
chemical analysis of more mature fetal kidneys (14- and
20-week-old human gestation kidneys) showed that de-
veloping glomeruli, especially capillary stage, also stain
positive for SCL (Fig. 2G, arrowheads). Higher magnifi-
cation demonstrated specific staining of glomerular en-
dothelial cells, based on their morphology and localiza-
tion within the glomerulus, and of red blood cells (Fig. 2I
and J). Maturing tubules (proximal, distal, and collecting)
were all negative for SCL (data not shown). The control
sections of nephrogenic cortex and developing glomeruli
shown in Figure 2C and H, respectively, demonstrate min-
imal background staining, confirming the specificity of
the immunohystochemical results. Thus, the SCL protein
is detected throughout human nephrogenesis with a spe-
cific immunohystochemical staining pattern of cells of the
nephrogenic cortex and glomeruli.
SCL 3′En expression in the developing kidney
Because SCL expression is developmentally regulated
in the kidney, SCL 3′En activity was examined to deter-
mine whether there is a correlation between the expres-
sion of SCL and the activity of its major hemoangioblastic
regulatory element. We assessed the activity of this en-
hancer in embryonic kidneys obtained from mice trans-
genic for the +6E5/lacZ/3′En construct. Whole-mount
X-gal staining was used to assess transgene expression in
E13, E14, E16, and adult kidneys. As shown in Figure 3A
and B in low magnification, lacZ is highly expressed in
the E13 kidneys, particularly in cells of the renal mes-
enchyme residing in close proximity to the comma- and
S-shaped primitive nephrons (Fig. 3C and D), whereas
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Fig. 3. Expression of +6E5/lacZ/3′En transgene in developing mouse
embryonic kidneys. X-galactosidase (X-gal) staining of embryonic day
13 (E13) (A to F), E14 (G and H), E16 (I and J), and adult kidneys
(K and L). (A and B) Low magnification images (original, ×10 and
×20, respectively) show abundant lacZ expression in the nephrogenic
cortex. (C and D) Positive X-gal staining in cells of the mesenchyme
surround comma and S-shaped primitive nephrons (PN). (E and F)
epithelial structures were all negative. Furthermore,
higher magnification revealed prominent lacZ staining
in cells resembling less-differentiated mesoderm cells
(Fig. 3E, arrowheads) and in endothelial cells organized
in capillaries (Fig. 3F, arrow). There was relatively less
expression of lacZ in the E14 kidneys (Fig. 3G and H),
whereas in E16 kidneys prominent X-gal staining was ob-
served in developing glomeruli, which start to appear in
E15 kidneys (Fig. 3I and J). In adult kidneys, although
significantly less abundant, expression of lacZ was still
observed in glomeruli, peritubular capillaries, and inter-
estingly also in scattered interstitial cells (Fig. 3K and L).
Therefore, the robust activity of the regulatory 3′En in
the developing kidney is closely related to that of SCL
protein and mRNA.
In vitro analysis of expression of SCL 3′En
In addition to the delineation of the in vivo expres-
sion pattern of the SCL 3′En, we examined its activity
by luciferase reporter assays in various cell lines. For
these experiments we used the following cell lines: COS-
7, derived from an adult African green monkey kid-
ney; MDCK, an epithelial cell line derived from adult
cocker spaniel kidney; and 293-T, derived from human
embryonic kidney and transformed by the sv-40 T anti-
gen. For controls, we used nonrenal cell lines: U2OS,
osteosarcoma-derived cell line, and NIH-3T3, human em-
bryonic fibroblast cell line, as well as a sv-40 T antigen
transformed NIH-3T3 cell line to rule out nonspecific
activation in a transformed cell line. Interestingly, the
+6e5/lacZ/3′En vector directed the expression of lacZ
only in the human embryonic kidney cell line 293-T but
not in any of the other renal or control cell lines (Fig. 4).
DISCUSSION
Recent studies suggest that there may be unexpected
plasticity in the relationship between metanephric re-
nal mesenchymal cells and other professional cell fates
apart from epithelial cells of the nephron. For in-
stance, Almeida-Porada et al [3] showed that human
metanephric mesenchymal cells engraft and demonstrate
High magnification images (original, ×100) show prominent lacZ stain-
ing mesodermal cells (E, arrowheads) and endothelial cells organized in
capillaries (Cap) (F, arrow). Note negative staining of intracapillary ery-
throcytes is marked with asterisks. (G and H) Reduced lacZ expression
in E14 kidneys is shown in low (original, ×20) and higher magnification
(original, ×40), respectively, whereas E16 kidneys demonstrate promi-
nent lacZ staining (original, ×20) (I), especially in developing glomeruli
(original, ×100) (J). (K and L) X-gal staining of adult kidneys shows
overall reduced lacZ expression that localizes to glomeruli [low mag-
nification in (K) (original, ×10, arrowheads) and higher magnification
in (L) (original, ×100)], peritubular capillaries (K, Cap), and scattered
interstitial cells (L, right upper inset).
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Fig. 4. Reporter assays for the determination of stem cell leukemia
(SCL) regulatory element activity (SCL 3′ enhancer) in various re-
nal and nonrenal cell lines. b-galactosidase reading demonstrates that
+6e5/lacz/3 enhancer vector directed the expression of lacZ only in the
human embryonic kidney cell line 293-T, but not in any of the other cell
lines analyzed (transient transfection and reporter assay are detailed in
the Methods section).
differentiation into CD34+ HSCs after transplanta-
tion into sheep fetuses. The transplanted human renal
cells produced multilineage hematopoietic engraftment.
Oliver et al [2] demonstrated that a metanephric mes-
enchymal cell line (7.1.1 cells) and primary cultures
of metanephric mesenchymal cells express vascular en-
dothelial growth factor receptor 2 and Tie-2 and sug-
gested that these epithelia-generating cells may also
differentiate into endothelial cells. Similarly, we have pre-
viously shown that very early porcine kidney precursors
can give rise to organized blood vessels after transplanta-
tion into immunodeficient mice [4]. It is therefore of great
interest to determine the expression of a gene, which has
been shown to be capable of integrating bipotential infor-
mation needed for blood and endothelial development,
during kidney ontogeny. Moreover, if cells that posses
dormant hemogenic and vasculogenic potential reside in
the adult kidney and could be activated in manner anal-
ogous to embryonic induction [20], they might be an im-
portant factor in regeneration after injury.
Quantitative gene expression measurements, immuno-
histology and in vitro and in vivo regulatory element anal-
yses combine together to suggest a role for SCL in kidney
development. Real-time reverse transcription (RT)-PCR
of total kidney RNA demonstrates that SCL mRNA is de-
velopmentally regulated in the murine kidney with high-
est levels in late nephrogenesis and a significant decrease
in the postnatal period. Importantly, prominent transcript
levels are already noted early in nephrogenesis with a
slight reduction prior to induction of peak mRNA levels.
These temporal changes correlate with the extent of X-
gal staining in developing mouse kidneys transgenic for
the distinct hematopoietic and endothelial 3′En of SCL
and with its cell-specific expression pattern. Thus, in early
mouse nephrogenesis, prior to the induction of glomeruli
(E13), there is abundant expression of SCL 3′En, which
is restricted predominantly to clusters of mesoderm cells
of the nephrogenic mesenchyme in proximity to primi-
tive nephrons and also to small capillaries. The in vitro
demonstration that the SCL 3′En is activated exclusively
in an embryonic kidney-derived cell line, which has been
recently characterized and was shown to express mes-
enchymal cell markers, is consistent with this finding [21].
Our data therefore demonstrate that the
+6E5/lacZ/3′En construct directed lacZ expression
to presumptive mesodermal progenitors at E13 mouse
kidneys. Later on, with the advent of glomerulogenesis
(E16), extensive transgene expression is found predom-
inantly in the developing glomeruli. This cell-specific
pattern of expression was very similar to that displayed
by immunostaining for SCL protein in developing human
kidneys. Respectively, in the embryonic (10 weeks) and
fetal (20 weeks) human kidneys, SCL protein mainly
localizes to cells of the metanephric mesenchyme and to
developing glomeruli.
Our findings of SCL and SCL 3′En expression in per-
itubular and glomerular blood vessels are in good agree-
ment with several experiments which showed both to
be expressed in endothelial cells during embryogene-
sis and adult tissues [18, 22, 23]. Accordingly, we could
also demonstrate continued lacZ expression in mature
glomeruli and peritubular capillaries of adult transgenic
kidneys, and even in some interstitial cells.
The pattern of SCL expression during mammalian kid-
ney development indicates that SCL may be important
in the early differentiation and growth of specific cells
within the metanephric mesenchyme. This hypothesis is
supported by several lines of evidence. First, early stud-
ies in cell lines and primary hemopoietic cells support a
role for SCL in the control of proliferation, self-renewal,
terminal differentiation, and survival [24, 25]. Second,
SCL is expressed in early mesenchymal progenitors of
the zebra fish pronephros and when overexpressed spec-
ifies hemangioblast development [14]. Third, GATA and
Ets transcription factors, which regulate the SCL stem cell
enhancer and coactivate SCL transcription [26], were also
shown to be expressed in the mammalian metanephros
[27, 28].
It has been recently demonstrated that rather than in-
growth of vessels into the developing kidney, endothelial
precursors residing in the metanephrogenic mesenchyme
itself give rise, at least in part, to glomerular capillar-
ies and microcirculation of the developed kidney [1, 29].
Whether SCL and its regulatory subunits function in the
specification of a population of such precursor cells in the
embryonic renal mesenchyme and are therefore impor-
tant to glomeular development remains to be explored.
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Moreover, in the light of previous evidence that SCL
is expressed in the hemangioblast [14] and the sugges-
tion that in early embryogenesis the SCL 3′En directs
expression to mesodermal cells as they are activating
the transcriptional programs necessary for hematopoi-
etic and endothelial differentiation [15, 16], metanephric
SCL-expressing cells may represent less committed re-
nal precursor cells that are able to generate blood and/or
endothelium, in addition to epithelia.
CONCLUSION
The present study demonstrates that SCL gene and
protein expression and the activity of the SCL stem cell
enhancer are developmentally regulated in the mam-
malian kidney. The early and specific expression of SCL
suggests a role for this hematopoietic and endothelial
master regulator in the differentiation and growth of the
mammalian kidney.
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